Sramek 1997.

Methods	1. Randomized 2. Double blind 3. Two parrallel groups: ‐Buspirone 60 mg/d ‐Buspirone 90 mg/d 4. Duration: 8 weekds with 7‐day placebo lead‐in phase 5. Analysis: patient data included if the patient completed at least 3 weeks of the double‐masked treatment phase (120/137)
Participants	1. Diagnosis: GAD (DSM‐III‐R) 2. N = 137 3. Age (mean and SD) Buspirone 60 mg/d = 33.6 (10.4) Buspirone 90 mg/d = 31.3 (8.5) Sex: 46.7% females Setting: outpatients History excluded any significant psychiatric disorder other than GAD
Interventions	1. Buspirone 60mg/d (N = 68) 2. Buspirone 90 mg/d (N = 69)
Outcomes	1. dropout rates 2. HAM‐A 3. CGI 4. Zung Self‐Rating Anxiety Scale 5. HAM‐D
Notes	Study supported by Bristol‐Myers Squibb
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear